Skip to main content

Table 1 The data of demographic and clinical characteristics

From: Comparison of the efficacy and safety of sedation protocols with the use of dexmedetomidine–remifentanil and propofol–remifentanil during percutaneous closure of atrial septal defects: a randomized clinical trial

 

D–R group (n = 29)

P–R group (n = 30)

Age (y)

45.34 ± 15.80

43.53 ± 16.31

Women, n (%)

20 (69.0%)

24 (80.0%)

Height (cm)

162.03 ± 8.34

160.03 ± 8.05

Weight (kg)

57.02 ± 10.06

57.88 ± 11.06

BMI (kg/m2)

21.62 ± 2.91

22.37 ± 3.19

ASA status (II/III), n

22/7

24/6

Snoring history, n (%)

8 (27.6%)

10 (33.3%)

Smoking history, n (%)

7 (24.1%)

5 (16.7%)

ASD size (mm)

18.96 ± 7.51

17.77 ± 6.88

PASP (mm Hg)

41.48 ± 9.04

39.03 ± 16.31

Qp/Qs

2.27 ± 0.32

2.18 ± 0.26

  1. D–R group: dexmedetomidine–remifentanil group; P–R group: propofol–remifentanil group; BMI: body mass index; ASA: American Society of Anesthesiologists; ASD: atrial septal defect; PASP: pulmonary artery systolic pressure; Qp/Qs: pulmonary to systemic blood flow ratio
Back to article page

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us